|
1
|
Spyratos D, Zarogoulidis P, Porpodis K, et
al: Preoperative evaluation for lung cancer resection. J Thorac
Dis. 6 Suppl 1:S162–S166. 2014.
|
|
2
|
Sculier JP, Meert AP and Berghmans T:
Updates in oncology. Eur Respir Rev. 23:69–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barlesi F, Pujol JL and Daures JP: Should
chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC)
be platinum-based? A literature-based meta-analysis of randomized
trials. J Clin Oncol. 23:72132005.
|
|
5
|
D'Addario G, Pintilie M, Leighl NB, Feld
R, Cerny T and Shepherd FA: Platinum-based versus
non-platinum-based chemotherapy in advanced non-small-cell lung
cancer: a meta-analysis of the published literature. J Clin Oncol.
23:2926–2936. 2005.PubMed/NCBI
|
|
6
|
Yan D, Wei P, An G and Chen W: Prognostic
potential of ERCC1 protein expression and clinicopathologic factors
in stage III/N2 non-small cell lung cancer. J Cardiothorac Surg.
8:1492013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leibeling D, Laspe P and Emmert S:
Nucleotide excision repair and cancer. J Mol Histol. 37:225–238.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fuertes MA, Castilla J, Alonso C and Perez
JM: Cisplatin biochemical mechanism of action: from cytotoxicity to
induction of cell death through interconnections between apoptotic
and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar
|
|
9
|
Sakano S, Ogawa S, Yamamoto Y, Nishijima
J, Miyachika Y, Matsumoto H, Hara T and Matsuyama H: ERCC1 and
XRCC1 expression predicts survival in bladder cancer patients
receiving combined trimodality therapy. Mol Clin Oncol. 1:403–410.
2013.PubMed/NCBI
|
|
10
|
Rosell R, Taron M, Camps C and
Lopez-Vivanco G: Influence of genetic markers on survival in
non-small cell lung cancer. Drugs Today (Barc). 39:775–786. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergot E, Levallet G, Campbell K, Dubois
F, Lechapt E and Zalcman G: Predictive biomarkers in patients with
resected non-small cell lung cancer treated with perioperative
chemotherapy. Eur Respir Rev. 22:565–576. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gurubhagavatula S, Liu G, Park S, Zhou W,
Su L, Wain JC, Lynch TJ, Neuberg DS and Christiani DC: XPD and
XRCC1 genetic polymorphisms are prognostic factors in advanced
non-small-cell lung cancer patients treated with platinum
chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradley J, Graham MV, Winter K, Purdy JA,
Komaki R, Roa WH, Ryu JK, Bosch W and Emami B: Toxicity and outcome
results of RTOG 9311: a phase I-II dose-escalation study using
three-dimensional conformal radiotherapy in patients with
inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol
Phys. 61:318–328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lord RV, Brabender J, Gandara D, et al:
Low ERCC1 expression correlates with prolonged survival after
cisplatin plus gemcitabine chemotherapy in non-small cell lung
cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
15
|
Lee MR, Cho SH, Kim DC, Lee KC, Lee JH,
Kwon HC, Lee HW and Lee SE: Concordance between
immunohistochemistry and FISH (fluorescence in situ hybridization)
& SISH (silver in situ hybridization) for assessment of the
HER2. Cancer Res. 72 Suppl 3:PD02–PD06. 2012.
|
|
16
|
Besse B, Olaussen KA and Soria JC: ERCC1
and RRM1: ready for prime time? J Clin Oncol. 31:1050–1060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Friboulet L, Olaussen KA, Pignon JP, et
al: ERCC1 isoform expression and DNA repair in non-small-cell lung
cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang MC: Letter to the editor regarding
‘Seol H, Lee HJ, Choi Y, et al: Intratumoural heterogeneity
of HER2 gene amplification in breast cancer: its
clinicopathological significance’. Mod Pathol. 26:609–610.
2013.
|
|
19
|
Bachtiary B, Boutros PC, Pintilie M, et
al: Gene expression profiling in cervical cancer: an exploration of
intratumor heterogeneity. Clin Cancer Res. 12:5632–5640. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Michor F and Polyak K: The origins and
implications of intratumor heterogeneity. Cancer Prev Res (Phila).
3:1361–1364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Burrell RA, McGranahan N, Bartek J and
Swanton C: The causes and consequences of genetic heterogeneity in
cancer evolution. Nature. 501:338–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Merlo LM and Maley CC: The role of genetic
diversity in cancer. J Clin Invest. 120:401–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ng CK, Pemberton HN and Reis-Filho JS:
Breast cancer intratumor genetic heterogeneity: causes and
implications. Expert Rev Anticancer Ther. 12:1021–1032. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anaka M, Hudson C, Lo PH, Do H, Caballero
OL, Davis ID, Dobrovic A, Cebon J and Behren A: Intratumoral
genetic heterogeneity in metastatic melanoma is accompanied by
variation in malignant behaviors. BMC Med Genomics. 6:402013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Losi L, Baisse B, Bouzourene H and
Benhattar J: Evolution of intratumoral genetic heterogeneity during
colorectal cancer progression. Carcinogenesis. 26:916–922. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saeki R, Nagai H, Kaneko S, Unoura M,
Yamanaka N, Okamoto E, Kobayashi K and Matsubara K: Intratumoral
genomic heterogeneity in human hepatocellular carcinoma detected by
restriction landmark genomic scanning. J Hepatol. 33:99–105. 2000.
View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sipos F, Constantinovits M and Műzes G:
Intratumoral functional heterogeneity and chemotherapy. World J
Gastroenterol. 20:2429–2432. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bedard PL, Hansen AR, Ratain MJ and Siu
LL: Tumour heterogeneity in the clinic. Nature. 501:355–364. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bustin SA, Benes V, Garson JA, et al: The
MIQE guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Greaves M and Maley CC: Clonal evolution
in cancer. Nature. 481:306–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jian-Wei B, Yi-Min M, Yu-Xia S and
Shi-Qing L: Expression levels of ERCC1 and RRM1 mRNA and clinical
outcome of advanced non-small cell lung cancer. Pak J Med Sci.
29:1158–1161. 2013.PubMed/NCBI
|
|
33
|
Yamashita F, Azuma K, Yoshida T, Yamada K,
Kawahara A, Hattori S, Takeoka H, Zaizen Y, Kawayama T, Kage M and
Hoshino T: Prognostic value of EGFR mutation and ERCC1 in patients
with non-small cell lung cancer undergoing platinum-based
chemotherapy. PLoS One. 8:e713562013. View Article : Google Scholar : PubMed/NCBI
|
